Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
7 drugs in development
By Therapeutic Area
top 4
R&D Momentum
77/100
Pipeline Velocity
50/100
Trial Completion Rate
87/100
Pipeline Concentration
26/100
Pipeline Freshness
7/100
Strategic Signals
Activity
Last 14 days
Feasibility of a Self-Hosted Vision-Language Model for Detecting Caregiver Contact and External Support, the Observable Criteria That Define GMFCS Levels, From Multi-View Movement Video in Children Aged 2 to 6 Years With Cerebral Palsy: A Two-Center Diagnostic Accuracy Study
A Phase 2, Randomized, Double-Blind, Parallel Group, Exploratory Study to Evaluate the Efficacy and Safety of PCA Regimen of VVZ-149 Injections for the Treatment of Post-Operative Pain
Effects of Individualized Positive End-expiratory Pressure (PEEP) on Intrinsic PEEP and Stroke Volume During One-lung Ventilation: a Single-center, Randomized Crossover Study
Lazertinib and Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment: A Phase II Multi-center Trial
Establishing a Wearable Eye-Tracking Protocol and Candidate Gaze-Action Metrics for Goal-Directed Bimanual Task Performance in Children With Cerebral Palsy
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)